Objective To investigate the changes of plasma quantity of Tissue Factor (TF) and Tissue Factor Pathway Inhibitor (TFPI) in different type of Acute coronary syndrome (ACS) patients and the association between Tissue Factor Pathway and Coronary Heart Disease and the application prospects of using TFPI to cure the ACS patients.
Methods This study was conducted with 66 coronary heart disease (CHD) patients and 22 healthy adults. The blood specimens were collected before using Low molecular weight heparin (LMWH) inACS patients; and the blood specimens of Stable angina pectoris (SAP) patients and healthy adults were collected on the second morning with a fasting status. After centrifugal treatment, the plasma was saved in a Ultra-low temperature refrigerator. Coronary angiography was carried out on each one of the selected objects, and the quantity levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein –cholesterol (HDL-C) and low density lipoprotein –cholesterol (LDL-C) was detected. The plasma TF and TFPI quantity was measured by ELISA.
Results The plasma TF antigen levels were highter in the Acute myocardial infarction (AMI) and Unstable angina pectoris (UAP) groups than in Stable angina pectoris (SAP) and control groups (161.08±20.90 and 152.76±20.66 pg/ml vs 99.72±16.75 and 94.32±12.93 pg/ml, p<0.05), there was no significant difference between the AMI group and UAP group, SAP group and control group (p>0.05). The plasma TFPI-1 antigen levels were highter in the AMI and UAP groups than in the SAP and control groups (32.05±8.52 and 31.49±10.61 ng/ml vs 19.93±9.22 and 19.21±9.60 ng/ml, p<0.05). The plasma TFPI-2 antigen levels were highter in the AMI and UAP groups than in the SAP and control groups (4.56±0.96 and 4.73±1.04 ng/ml vs 2.43±1.07 and 2.06±0.64 ng/ml, p<0.05).
Conclusions The plasma TF, TFPI-1, TFPI-2 antigen levels of ACS patients are higher than those of SAP patients and healthy adults, the result indicates ACS patients have an abnormally activity of coagulation system, the tissue factor pathway plays an important role in ACS patients, during our clinical work, we can reduce the incidence of coronary event through actively controlling plasma levels of tissue factor pathway in CHD patients; There were positive relationships between plasma TF, TFPI-1, TFPI-2 quantities and serum TC, LDL-C quantities, we can reduce the activity of tissue factor pathway through controlling the quantities of TC and LDL-C.
- Coronary heart disease
- tissue factor
- tissue factor pathway inhibitor